Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Methotrexate Market

Methotrexate Market Size

  • Report ID: GMI6835
  • Published Date: Oct 2023
  • Report Format: PDF

Methotrexate Market Size

Methotrexate Market size was valued at USD 553 million in 2022 and is estimated to account for USD 921 million by 2032.

 

Methotrexate is a versatile medication that is used to treat a variety of medical conditions, including cancer, autoimmune diseases, and severe skin disorders. It is classified as a disease-modifying anti-rheumatic drug (DMARD) when used for autoimmune diseases and as a chemotherapeutic agent for cancer treatment. Methotrexate is a medication that has been used for several decades for the treatment of various cancers. It belongs to a class of drugs known as antimetabolites and is considered as a cytotoxic chemotherapy agent. The methotrexate market is growing majorly owing to increasing patient population base with chronic health conditions such as cancer, autoimmune disorders, rheumatoid arthritis, among others.
 

For instance, according to estimates, about 28.4 million new cancer cases will arise worldwide by 2040, which is an increase from 19.3 million cases from the year 2020, a 47% rise. This prediction is primarily based on the increasing ageing population and is further accelerated by the rising incidence of risk factors such as smoking, unhealthy lifestyle, among others in various regions of the world. Thus, the rising prevalence of cancer is estimated to augment the market trends.
 

The increasing number of pharmaceutical research and development activities is anticipated to drive the market growth in the coming years. Development of novel drugs with an aim to achieve the unmet medical requirements are amongst the primary factors of research-based pharmaceutical & biotechnology companies’ growth. The pharmaceutical sector develops several novel drugs that offer valuable clinical benefits. The surging number of investments by government as well as private players are amongst the prime variables that will propel the number of pharmaceutical research and development activities.

Although methotrexate is well-established and primarily focused on optimizing its use in existing conditions such as cancer, psoriasis, and rheumatoid arthritis, its potential new applications are being explored. For instance, the use of methotrexate in the treatment of ankylosing spondylitis was investigated. This clinical trial aimed to evaluate the effectiveness of methotrexate in the treatment of ankylosing spondylitis, a type of inflammatory arthritis.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global methotrexate industry was valued at USD 553 million in 2022 and is estimated to account for USD 921 million by 2032 as methotrexate is a versatile medication that is used to treat a variety of medical conditions, including cancer, autoimmune diseases, and severe skin disorders.

Rheumatoid arthritis (RA) segment accounted for over USD 250 million in the year 2022, supported by the growing prevalence of people suffering from the disease in developed as well as developing economies.

U.S. methotrexate market accounted for USD 165.3 million in 2022 and is predicted to witness substantial growth through 2032, attributed to the significant healthcare expenditure, supportive government initiatives, high number of pharmaceutical companies, and rising disease awareness.

Novartis AG (Sandoz), Merck & Co., Inc, Lonza, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd, Fermion (Orion Corporation), Avra Laboratories Pvt Ltd, LGM Pharma, and Rochem International Inc among others.

Methotrexate Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 230
  • Countries covered: 23
  • Pages: 164
 Download Free Sample